MediciNova, Inc. announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova?s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center. The presentation details are as follows: Title: Immunohistochemistry evaluation on pre-treatment tumor tissue predicts treatment response to MN-166 (ibudilast) and Temozolomide combination therapy in glioblastoma patients Session Name: Poster Session Session Date: Friday November 17, 2023 Session Time: 7:30 PM - 9:30 PM.

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).